API & IP Brief: FDA CGT Approvals Review, Sodium Thiosulfate Patent Ruling & Biopharma Updates
API & IP Intelligence Brief: FDA Competitive Generic Therapy (CGT) Review & Purity Patent Rulings
Target Keywords: Competitive Generic Therapy, CGT exclusivity, FDA ANDA approvals, Zydus Lifesciences, Amneal lanreotide, Hope Medical v Accord, sodium thiosulfate patent, API purity specifications, Paragraph IV litigation, Teva R&D Day
Six-Month FDA Competitive Generic Therapy (CGT) Review (Apr – Oct 2026)
Between April 28 and October 19, 2026, the FDA approved 45 Abbreviated New Drug Applications (ANDAs) holding Competitive Generic Therapy (CGT) designations, up from 41 in the prior six-month period
Under Section 506H of the FD&C Act, CGT incentivises entry into off-patent or sole-source drugs facing inadequate generic competition
Key CGT Execution & Market Trends
Indian Filers Lead Approvals: Indian pharmaceutical companies secured 27 of the 45 total approvals (60%) and 7 of the 12 exclusivity-eligible products
. Zydus led with 8 approvals and 3 eligible products, including the Climara Pro transdermal patch, ascorbic acid injection, and indocyanine green (already launched under exclusivity) . High-Barrier Dosage Forms Dominate: Complex, non-oral solid products accounted for 32 of the 45 approvals (71%) and 10 of the 12 exclusivity-eligible candidates
. Sterile injectables, transdermal patches, oral solutions, and inhalers carry manufacturing hurdles that naturally restrict competition . Commercial Speed Determines Exclusivity: Of the 12 eligible products, five triggered exclusivity through timely launch, led by Amneal’s high-value generic lanreotide (Somatuline Depot) prefilled syringe
. Conversely, three applicants (Beloteca’s iloprost, Macleods’ rifapentine, and Umedica’s zolpidem) forfeited exclusivity by missing the 75-day launch deadline, underscoring the need to have Drug Master Files (DMFs) and launch inventory ready prior to GDUFA dates .
Intellectual Property: Delaware Court Upholds "Ultrapure" API Patents (Hope Medical v. Accord)
On October 13, 2026, the US District Court for the District of Delaware ruled entirely in favour of Hope Medical Enterprises against Accord Healthcare (a subsidiary of Intas Pharmaceuticals) regarding Sodium Thiosulfate Injection (250 mg/mL)
The litigation centred on three patents (US 11,753,301; US 8,496,973; and US 9,345,724) claiming pharmaceutical-grade sodium thiosulfate defined by strict purity specifications that simultaneously cap 22 trace impurities, including mercury (≤0.05 ppm), aluminium (≤2 ppm), and non-purgeable organic carbon (≤10 ppm)
Anhydrous Design-Around Fails: Accord used anhydrous sodium thiosulfate API to avoid older claims reciting the pentahydrate form
. The court found infringement anyway, noting that solution concentrations are calculated on a pentahydrate basis, and upheld Hope’s continuation patent (‘301), which covers any hydrate form . Purity Specifications Are Patentable: The court rejected obviousness and prosecution laches defences, holding that purifying an inorganic salt to simultaneously satisfy stringent FDA-requested limits was unpredictable rather than routine optimisation. For API manufacturers, this confirms that stringent quality thresholds and pending patent continuations can block generic entry even on century-old molecules
.
Biopharma Pipeline & Regulatory Highlights
Teva Targets $6–7 Billion in Innovative Revenue: At its R&D Day, Teva outlined its growth trajectory under its "Pivot to Growth" strategy, having more than doubled innovative medicine revenues since 2023
. NeOnc Granted FDA Type B Meeting: Clinical-stage biopharma NeOnc Technologies secured a January 2027 FDA End-of-Phase meeting to discuss an accelerated approval pathway and Phase 3 confirmatory trial design for intranasal NEO100 in recurrent IDH-mutant grade 4 astrocytoma
.
Contents
Competitive Generic Therapy (CGT): Six-Month Review of FDA Approvals (Apr – Oct 2026)
General information
Teva Shares Innovative Pipeline Updates and Unveils Path to Future Growth at R&D Day, Targeting $6–7 Billion in Innovative Medicines Revenue by 2030
NeOnc Technologies Granted FDA Type B End-of-Phase Meeting to Discuss Potential Accelerated Approval Pathway and Phase 3 Confirmatory Trial for Intranasal NEO100
Intellectual Property
Hope Medical v. Accord (Intas): Delaware court upholds "ultrapure" sodium thiosulfate API patents against ANDA filer
Competitive Generic Therapy (CGT): Six-Month Review of FDA Approvals (Apr – Oct 2026)
- Faster, more interactive review: designated applicants can request development meetings, and FDA uses mid-review-cycle teleconferences and cross-disciplinary review teams, although designation does not guarantee a shorter GDUFA goal date.
- 180 days of protection from later generics: for a niche product with one or no generic competitors, this window often earns most of the product's lifetime profit.
- A route where Paragraph IV does not apply: CGT exclusivity rewards entry into off-patent, sole-source or shortage-prone products that offer no patent-challenge exclusivity.
- The clock starts at launch, not approval, so the applicant controls when the 180 days begin, but the 75-day forfeiture rule stops it from "parking" the exclusivity.
Status of CGT exclusivity
Five of the 12 eligible applicants have triggered exclusivity; three of the eight decided cases ended in forfeiture.
By dosage form
32 of the 45 approvals (71%) and 10 of the 12 eligible products are not conventional tablets or capsules.
- Exclusivity is the exception, not the rule. Only 12 of 45 approvals were eligible. Most designated products had another applicant approved first, or patents or exclusivities listed when the ANDA was filed. More filers now chase the same niches: pitolisant (Lupin, Novitium), prucalopride (Alembic, Micro Labs) and calcium gluconate (Cipla, Caplin) each drew two CGT approvals from different applicants in this window.
- The 75-day rule bites. Three of the eight decided cases forfeited (iloprost, rifapentine, zolpidem 7.5 mg), compared with two of eleven in the previous six months. Two of the winners launched late in the window (DMSO on day 66, propranolol on day 70). API supply, commercial batches and distribution must be ready before approval, not after.
- Value sits in hard-to-make dosage forms. Sterile injectables, peptide depots, transdermal patches, oral liquids and inhalation products account for 10 of the 12 eligible approvals. Their manufacturing barriers keep competitor numbers low, which is exactly the situation CGT rewards.
- Indian companies dominate the list. They hold 27 of 45 approvals and 7 of 12 eligible products. Zydus leads with 8 approvals and three eligible products (Climara Pro, ascorbic acid, indocyanine green), and indocyanine green is already under exclusivity. Lupin (3), Dr. Reddy's (2), Sun (2), Cipla, Alembic, Micro Labs, Macleods, Natco, Concord, Caplin, Rubicon, Orbicular, Umedica, Encube and Aurobindo (Aurolife) also feature.
- Amneal holds the most valuable exclusivity of the period. Its lanreotide prefilled syringe is an ANDA generic of Somatuline Depot, marketed on 21 September 2026, with exclusivity running to about March 2027. CGT exclusivity blocks only later ANDAs; Cipla's lanreotide, approved through a 505(b)(2) NDA, is a separate product, and its US supply has been paused since late 2025 because of FDA inspection issues at its partner's plant.
- This analysis uses the FDA's Competitive Generic Therapy Approvals list, as updated on 22 October 2026 (approvals to 19 October 2026). As far as possible, duplicate entries were counted only once.
- Applicants were grouped as Indian by parent company (for example, Zydus Lifesciences Global FZE with Zydus, Aurolife with Aurobindo).
- Four exclusivity determinations were still open; their status may have changed after FDA's last update.
- For generic filers and API makers, CGT rewards the first applicant that is both approved and on the market within 75 days. A filed DMF, secured API supply and launch stock before the GDUFA date are as important as the designation itself.
- The number of CGT-eligible approvals that are launched is a useful measure of a generic company's execution in niche products; in this period, Zydus and Amneal stand out.
General information
Teva Shares Innovative Pipeline Updates and Unveils Path to Future Growth at R&D Day, Targeting $6–7 Billion in Innovative Medicines Revenue by 2030
NeOnc Technologies Granted FDA Type B End-of-Phase Meeting to Discuss Potential Accelerated Approval Pathway and Phase 3 Confirmatory Trial for Intranasal NEO100
Intellectual Property
Hope Medical v. Accord (Intas): Delaware court upholds "ultrapure" sodium thiosulfate API patents against ANDA filer
- Infringement: the 301 patent was held infringed as a matter of law; Accord's only argument, that its ranges merely overlap the claimed ranges, is foreclosed by Sunovion v. Teva (Fed. Cir. 2013). On the 973/724 claims, the court held that a skilled person measures sodium thiosulfate in solution on a pentahydrate basis, as Accord's own label, assay validation and FDA-requested specifications did. Making the solution from anhydrous API did not avoid infringement.
- Obviousness rejected: Accord relied on a 1917 synthesis patent (Hutchins) plus general knowledge. A confidential 2008 FDA letter asking Hope to meet 18 additional "aspirational" specifications supplied a motivation, but not a reasonable expectation of success: purifying an inorganic salt to all limits at once was unpredictable, not routine optimisation. Long-felt need, the failure of others (unapproved products withdrawn in 2010–11) and Hope's priority review supported non-obviousness.
- Written description upheld: "no greater than" means from the limit of detection up to the stated value, and Example 1 (for example 0.58 ppm aluminium) showed possession. Ranges that include values that are hard to achieve are not invalid on that basis alone.
- No prosecution laches: filing the 301 patent about 14 years after the first application, and months after Accord's notice letter, was not unreasonable for a company with no more than two employees, and Accord showed no prejudice. Drafting claims to capture a competitor's product is legitimate (PIN/NIP v. Platte).




